Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Santiago Barrio Garcia"'
Autor:
Maria Teresa Cedena Romero, Joaquin Martinez Lopez, Yanira Ruiz-Heredia, Jeffrey L. Wolf, José Morales Sánchez, Santiago Barrio Garcia, Rafael Rios, Thomas Martin, Rafael Alonso Fernández, Nina Shah, Sandy W. Wong
Publikováno v:
Blood. 136:42-43
Background Measurable residual disease (MRD) testing in multiple myeloma (MM) is increasingly being utilized in clinical trials for the assessment of disease response and as a prognostic tool for predicting response duration. However, there is only l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d5b3853bb00e6359c733278f089336f
https://doi.org/10.1182/blood-2020-140352
https://doi.org/10.1182/blood-2020-140352
Autor:
Maria Poza, Patricia López-Pereira, Gloria Figaredo García-Mina, Irene Zamanillo Herreros, Rodrigo Íñiguez García, Sandra Gómez-Rojas, Gloria Pérez Segura, Rosa Ayala, Tycho Baumann, Antonia Rodriguez Izquierdo, Santiago Barrio García, Alejandro Martín-Muñoz, Pilar Sarandeses, Enrique Revilla, Sara Dorado, Margarita Rodriguez, Joaquín Martínez-López, Ana Isabel Jimenez Ubieto
Publikováno v:
HemaSphere, Vol 7, p e8923396 (2023)
Externí odkaz:
https://doaj.org/article/c2de7fd24a57457b921acb0f85e0e532
Autor:
Nadine Rodhes, Raoul Tibes, Andreas Rosenwald, Matteo Claudio Da Via, Andoni Garitano-Trojaola, Thorsten Stuehmer, Eva Teufel, Martin Kortüm, Hermann Einsele, Ana Sancho, Torsten Haferlach, Santiago Barrio Garcia, Jürgen Groll
Publikováno v:
Blood. 132:5148-5148
Secondary Acute Myeloid Leukemia (sAML) accounts for 10-30% of all AML. It arises from a preexisting clonal disorder of hematopoiesis, such as myelodysplastic syndromes (MDS) or chronic myeloproliferative neoplasia (cMPN) in most cases (60-70%) or fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::596f3311fbafd47a5d9e327d7be0bcb4
https://doi.org/10.1182/blood-2018-99-118484
https://doi.org/10.1182/blood-2018-99-118484
Autor:
Thorsten Stuehmer, Hermann Einsele, Max Bittrich, Cornelia Vogt, Torsten Steinbrunn, Matteo Claudio Da Via, Larissa Haertle, K. Martin Kortüm, Umair Munawar, Santiago Barrio Garcia, Andoni Garitano-Trojaola, Thomas Haaf, Joaquin Martinez Lopez, Yanira Ruiz-Heredia, Ramya Potabattula
Publikováno v:
Blood. 132:404-404
Immunomodulatory drugs (IMiDs) and proteasome inhibitors (PI) are backbone agents in the treatment of Multiple Myeloma (MM). However, most patients develop drug resistance over time, with the underlying mechanisms poorly understood. Epigenetic modifi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b6fcc2df6707d8046cb52ca1d1fe8e4
https://doi.org/10.1182/blood-2018-99-118944
https://doi.org/10.1182/blood-2018-99-118944
Publikováno v:
Blood. 132:471-471
Mechanisms of drug resistance in Multiple Myeloma (MM) are poorly understood. Mutations and/or changes in the protein expression of the CRBN pathway and proteasome subunits have been identified to induce resistance to IMiDs and PIs. However, only few
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::39b58ed9c0ee2f46e30fa9bd06b98dc6
https://doi.org/10.1182/blood-2018-99-118700
https://doi.org/10.1182/blood-2018-99-118700
Autor:
Raoul Tibes, Andreas Rosenwald, Andoni Garitano-Trojaola, Harald Wajant, Eva Teufel, K. Martin Kortüm, Nadine Rodhes, Hermann Einsele, Torsten Haferlach, Matteo Claudio Da Via, Jennifer Kreckel, Santiago Barrio Garcia, Thorsten Stuehmer
Publikováno v:
Blood. 132:5132-5132
Acute Myeloid Leukemia (AML) is a genetically heterogenous disease characterized by clonal expansion of immature myeloid progenitors cells in the bone marrow (BM). Despite this genetic heterogeneity, AML patients share Leukemia associated oncogenes s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a832982ea2590f240b54c36e1de43765
https://doi.org/10.1182/blood-2018-99-118270
https://doi.org/10.1182/blood-2018-99-118270